We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $58.43 · 14 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Celldex Therapeutics stock (US15117B1035): Nasdaq-listed biotech trades quietly ahead of next cataly - AD HOC NEWS
Celldex Therapeutics stock (US15117B1035): Nasdaq-listed biotech trades quietly ahead of next cataly AD HOC NEWS
Celldex Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Celldex Therapeutics | SCHEDULE 13G/A: Others Moomoo
[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX) - Stock Titan
Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX) Stock Titan
Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1 - Stock Titan
Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1 Stock Titan
Celldex Therapeutics stock (US15117B1035): Wells Fargo raises price target to $54 - AD HOC NEWS
Celldex Therapeutics stock (US15117B1035): Wells Fargo raises price target to $54 AD HOC NEWS
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-1.06 | — | — | $858.9K | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.81 | — | — | $695K | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-1.74 | — | — | $5.85M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-1.1 | — | — | $2.65M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 13. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 05. 08. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 04. 20. | Barclays | — | Upgrade | Underweight → Overweight | — | Barclays: Underweight → Overweight |
| 2026. 03. 03. | Goldman Sachs | — | Maintain | Neutral → Neutral | — | Goldman Sachs: Neutral |
| 2026. 02. 26. | Stifel | — | Maintain | Buy → Buy | — | Stifel: Buy |
| 2025. 12. 18. | Barclays | — | Maintain | Underweight → Underweight | — | Barclays: Underweight |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.